CASE REPORT: MANAGEMENT OF GRAVES DISEASE DURING PREGNANCY
Date Issued
2022-10-13
Author(s)
M. Zivkovic Hristova
M. Dimitrovska
Abstract
Hyperthyroidism raises the risk of maternal and fetal complications. Hence early detection and treatment of hyperthyroidism in a pregnancy is imperative. Management of Graves' hyperthyroidism in pregnancy remains a challenge for physicians. The transplacental passage of maternal thyroid stimulating antibodies (TSHrAb) and antithyroid drugs (ATD) could have detrimental effect on fetal development. Additionally, maintaining sufficient thyroid
hormone levels in maternal circulation during the treatment with ATD is essential, as thyroid hormones are crucial factors for normal development of the fetus, particularly the fetal brain. Additionally, ATD must be carefully titrated in order to avoid fetal hyper-or hypothyroidism. One more concern of use of ATD in pregnancy is the potential risk for severe birth malformations when fetus is exposed to ATDs in 6 to 10th gestational week(gw) of pregnancy. We
present a pregnant woman at 6th gw with uncontrolled hyperthyroidism. Thyroxine and triiodothyronine values were four times above reference values, TSH was significantly suppressed and TSHrAb were 10fold increased. Ultrasound measurement of thyroid volume was >50ml. The patient was treated with maximum recommended doses At25 gw the TSHrAb significantly decreased and a careful reduction of ATD to a minimum maintenance dose was
achieved during the period 26 to 34gw. The outcome and course of the pregnancy was uneventful. Due to delicate balance of benefit and potential risk of use of ATD for optimal fetal development and fetal thyroid function management of hyperthyroidism in pregnancy requires teamwork between gynecologist and an endocrinologist.
hormone levels in maternal circulation during the treatment with ATD is essential, as thyroid hormones are crucial factors for normal development of the fetus, particularly the fetal brain. Additionally, ATD must be carefully titrated in order to avoid fetal hyper-or hypothyroidism. One more concern of use of ATD in pregnancy is the potential risk for severe birth malformations when fetus is exposed to ATDs in 6 to 10th gestational week(gw) of pregnancy. We
present a pregnant woman at 6th gw with uncontrolled hyperthyroidism. Thyroxine and triiodothyronine values were four times above reference values, TSH was significantly suppressed and TSHrAb were 10fold increased. Ultrasound measurement of thyroid volume was >50ml. The patient was treated with maximum recommended doses At25 gw the TSHrAb significantly decreased and a careful reduction of ATD to a minimum maintenance dose was
achieved during the period 26 to 34gw. The outcome and course of the pregnancy was uneventful. Due to delicate balance of benefit and potential risk of use of ATD for optimal fetal development and fetal thyroid function management of hyperthyroidism in pregnancy requires teamwork between gynecologist and an endocrinologist.
Subjects
File(s)![Thumbnail Image]()
![Thumbnail Image]()
Loading...
Name
Насловна.png
Size
240.43 KB
Format
PNG
Checksum
(MD5):49ea6a12e1c6443a1fd66be7999ccc68
Loading...
Name
Graves.png
Size
82.35 KB
Format
PNG
Checksum
(MD5):fb1f4d456ee0d2819a944f8a2fb15979